Veru Inc. VERU
2.09 USD -0.03 (-1.42%)
Regular-session close
2.09 0.00 0.00%
After hours · Nov 13, 4:00 PM ET
2.08 Day range 2.15
2.06 52-week range 4.23
- YTD
- -2.34%
- 1 year
- -16.73%
News
benzinga.com Veru To Present Phase 2b QUALITY Study Analysis Of Physical Function In Older Obesity Patients At ObesityWeek 2026 Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of metabolic diseases and oncology, today announced Veru’s Chief…
globenewswire.com Veru to Present New Results on Effects of Enobosarm on Physical Function in Older Patients Receiving GLP-1 RA from the Phase 2b QUALITY clinical study at ObesityWeek 2026 MIAMI, FL, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of metabolic…
benzinga.com WestPark Capital Initiates Coverage On Veru with Buy Rating, Announces Price Target of $28 WestPark Capital analyst Ed Arce initiates coverage on Veru (NASDAQ:VERU) with a Buy rating and announces Price Target of $28.
benzinga.com Veru Q3 EPS $(0.30) Beats $(0.32) Estimate Veru (NASDAQ:VERU) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.32) by 6.25 percent. This is a 40 percent increase over losses of $(0.50) per share…
benzinga.com Veru Completes Patient Enrollment In Phase 2b PLATEAU Clinical Trial To Evaluate Effect Of Oral Enobosarm 3 Mg Versus To Treat Obesity Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced…
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session - benzinga.com Veru Strikes Clinical Supply Agreement With Novo Nordisk To Mull Combination Of Enobosarm With Wegovy https://www.sec.gov/ix?doc=/Archives/edgar/data/863894/000143774926019478/veru20260601_8k.htm
benzinga.com Earnings Scheduled For May 13, 2026 - benzinga.com Earnings Scheduled For February 11, 2026
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session - benzinga.com Earnings Scheduled For December 17, 2025
benzinga.com Top Stocks With Earnings This Week: Micron, FuelCell, Carnival and More Investors are prepping for this week's earnings reports which include homebuilders, several apparel companies and a big tech company.
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session - benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session 
benzinga.com Earnings Scheduled For August 12, 2025 - benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com Earnings Scheduled For May 8, 2025
benzinga.com Earnings Scheduled For February 13, 2025 - benzinga.com Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic…
- benzinga.com Earnings Scheduled For February 8, 2024 Companies Reporting Before The Bell • Ares Management (NYSE:ARES) is expected to report quarterly earnings at $1.09 per share on revenue of $864.54 million.
- benzinga.com Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day Session Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at…
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 311 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday Friday's session saw 112 companies set new 52-week lows.
- benzinga.com 11 Consumer Staples Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday During Tuesday's session, 275 companies made new 52-week lows.
- benzinga.com Earnings Scheduled For August 10, 2023 Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million.
- benzinga.com Earnings Scheduled For May 11, 2023 Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings for its fourth quarter. • Exela Technologies (NASDAQ:XELA) is expected to report earnings for its…
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 220 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 76 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 93 stocks made new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 469 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 175 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday During Wednesday's session, 104 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 198 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday Thursday's session saw 337 companies set new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 479 stocks made new 52-week lows.- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 497 companies set new 52-week lows.
- benzinga.com Earnings Scheduled For February 9, 2023 Companies Reporting Before The Bell • AstraZeneca (NASDAQ:AZN) is expected to report quarterly earnings at $0.67 per share on revenue of $11.21 billion.
- benzinga.com Earnings Scheduled For December 5, 2022 Companies Reporting Before The Bell • DLH Hldgs (NASDAQ:DLHC) is likely to report quarterly earnings at $0.25 per share on revenue of $67.00 million.
- benzinga.com Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know Editor's note: This story has been corrected to reflect that the FDA deferred action on Amicus Therapeutics' Biologics License Application.
- benzinga.com Why Stabilis Solutions Shares Jumped Over 71%; Here Are 70 Biggest Movers From Yesterday Gainers
- benzinga.com Why Adamis Pharmaceuticals Is Trading Lower By Around 44%, Here Are 46 Stocks Moving In Wednesday's Mid-Day Session Gainers
- benzinga.com Why IN8bio Is Trading Higher By 46%, Here Are 54 Stocks Moving In Tuesday's Mid-Day Session Gainers NewAge, Inc. (NASDAQ: NBEV) rose 54.4% to $0.3220.
- benzinga.com Why FlexShopper Surged Over 47%; Here Are 104 Biggest Movers From Yesterday Gainers Digital Media Solutions, Inc. (NYSE: DMS) jumped 78.8% to close at $2.11. Digital Media Solutions recently reported worse-than-expected Q2 EPS and sales results.
- benzinga.com Earnings Scheduled For August 11, 2022 Companies Reporting Before The Bell • Magic Software (NASDAQ:MGIC) is projected to report quarterly earnings at $0.27 per share on revenue of $131.70 million.
- benzinga.com Alibaba, Zoom Video And 76 Biggest Movers From Yesterday Gainers Kaspien Holdings Inc. (NASDAQ: KSPN) shares climbed 161.9% to close at $6.81 on Monday on heavy volume amid mention of the stock on social media.
- benzinga.com Coinbase, Moderna And 56 Biggest Movers From Yesterday Gainers Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN) shares climbed 75.2% to close at $2.19 after the company announced it has developed a non-invasive blood sensor designated to alert…
- benzinga.com Why Is DoorDash Down By 8%? 38 Stocks Moving In Wednesday's Mid-Day Session Gainers Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN) shares surged 69.5% to $2.1199 after the company announced it has developed a non-invasive blood sensor designated to alert real-time…
- benzinga.com Earnings Scheduled For May 12, 2022 Companies Reporting Before The Bell • Chicago Atlantic Real (NASDAQ:REFI) is projected to report earnings for its first quarter.